Deborah J. Lenschow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Deborah J. Lenschow has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
Marissa C. Locke
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA
5 shared publicationsAlissa R. Young
Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA
4 shared publications- Lindsey E. Cook
Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA
4 shared publications Lindsey E. Fox
Affiliation Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America
4 shared publicationsBradley E. Hiller
Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA
3 shared publicationsKristen J. Monte
Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
3 shared publications
Latest Publications
- Open Access
MXRA8-dependent chikungunya virus infection in PDGFR + mesenchymal cells increases vascular permeability and facilitates hematogenous spread
Alphaviruses are mosquito-transmitted pathogens in the Togaviridae family that cause severe arthritogenic or encephalitic disease in humans. Swelling of peripheral joints and soft tissues is a hallmark of arthritogenic alphavirus infection, although the mechanism by which tissue edema occurs is not well understood. The cell surface protein, matrix remodeling- associated protein 8 (MXRA8), is a cell entry receptor for several arthritogenic alphaviruses. Global loss of MXRA8 expression in mice abrogates foot swelling and reduces virus dissemination. Here, we demonstrate that specific ablation of MXRA8 from platelet-derived growth factor receptor alpha (PDGFRα) cells, including fibroblasts, phenocopies the foot swelling and dissemination deficits observed in chikungunya virus (CHIKV)-infected global MXRA8 knock-out mice. Edema in the foot requires CHIKV infection of PDGFRα + cells, which enhances both infection efficiency and permeability of endothelial cells. CHIKV-induced vascular leakage requires both MXRA8 expression and vascular endothelial growth factor signaling and contributes to dissemination by enabling virus access to the bloodstream. Collectively, our study establishes the role of MXRA8-dependent cell tropism in CHIKV dissemination and pathogenesis.
Open AccessMXRA8-dependent chikungunya virus infection in PDGFR + mesenchymal cells increases vascular permeability and facilitates hematogenous spread
Alphaviruses are mosquito-transmitted pathogens in the Togaviridae family that cause severe arthritogenic or encephalitic disease in humans. Swelling of peripheral joints and soft tissues is a hallmark of arthritogenic alphavirus infection, although the mechanism by which tissue edema occurs is not well understood. The cell surface protein, matrix remodeling- associated protein 8 (MXRA8), is a cell entry receptor for several arthritogenic alphaviruses. Global loss of MXRA8 expression in mice abrogates foot swelling and reduces virus dissemination. Here, we demonstrate that specific ablation of MXRA8 from platelet-derived growth factor receptor alpha (PDGFRα) cells, including fibroblasts, phenocopies the foot swelling and dissemination deficits observed in chikungunya virus (CHIKV)-infected global MXRA8 knock-out mice. Edema in the foot requires CHIKV infection of PDGFRα + cells, which enhances both infection efficiency and permeability of endothelial cells. CHIKV-induced vascular leakage requires both MXRA8 expression and vascular endothelial growth factor signaling and contributes to dissemination by enabling virus access to the bloodstream. Collectively, our study establishes the role of MXRA8-dependent cell tropism in CHIKV dissemination and pathogenesis.
- Open Access
- 15 May 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (5) , 117360
ISG15 negatively regulates RIPK3-mediated cell death and viral pathogenesis
- 15 May 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (5) , 117360
Open AccessISG15 negatively regulates RIPK3-mediated cell death and viral pathogenesis
- Open Access
- 28 April 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (12)
Stabilizing and strengthening the US physician-scientist faculty workforce in academic medicine: a proposed institutional framework
Physician-scientists represent one of the most impactful, yet underrecognized, innovations of 20th century academic medicine. Defined by a commitment to full-time careers in investigative work, physician-scientists have repeatedly demonstrated a unique ability to identify and solve problems of unmet medical need in a focused and intentional manner using their dual training in clinical medicine and the scientific method as both stethoscope and scalpel. Unfortunately, while the value of physician-scientists has never been greater, the institutional infrastructure to support them has never been explicitly defined (1), a deficiency now amplified by mounting financial pressures from both clinical revenue models and an increasingly constrained research funding landscape (2, 3). This white paper reports the output of a consortium of academic medical centers, foundations, and professional societies seeking to remedy this deficiency. This consortium specifically developed a framework to formalize the career path of physician-scientist faculty into a professionally unified and financially sustainable structure amenable to adoption across US academic medical centers and health systems. Key components of this framework included an administratively operational definition of physician-scientists, and 3 central and interconnected pillars (academic, financial, and organizational) that are rooted in this foundational definition. Herein, we detail core concepts and concrete recommendations.
- 28 April 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (12)
Open AccessStabilizing and strengthening the US physician-scientist faculty workforce in academic medicine: a proposed institutional framework
Physician-scientists represent one of the most impactful, yet underrecognized, innovations of 20th century academic medicine. Defined by a commitment to full-time careers in investigative work, physician-scientists have repeatedly demonstrated a unique ability to identify and solve problems of unmet medical need in a focused and intentional manner using their dual training in clinical medicine and the scientific method as both stethoscope and scalpel. Unfortunately, while the value of physician-scientists has never been greater, the institutional infrastructure to support them has never been explicitly defined (1), a deficiency now amplified by mounting financial pressures from both clinical revenue models and an increasingly constrained research funding landscape (2, 3). This white paper reports the output of a consortium of academic medical centers, foundations, and professional societies seeking to remedy this deficiency. This consortium specifically developed a framework to formalize the career path of physician-scientist faculty into a professionally unified and financially sustainable structure amenable to adoption across US academic medical centers and health systems. Key components of this framework included an administratively operational definition of physician-scientists, and 3 central and interconnected pillars (academic, financial, and organizational) that are rooted in this foundational definition. Herein, we detail core concepts and concrete recommendations.
- 12 July 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (97) , eadn0178
Initiator cell death event induced by SARS-CoV-2 in the human airway epithelium
Virus-induced cell death is a key contributor to COVID-19 pathology. Cell death induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is well studied in myeloid cells but less in its primary host cell type, angiotensin-converting enzyme 2 (ACE2)–expressing human airway epithelia (HAE). SARS-CoV-2 induces apoptosis, necroptosis, and pyroptosis in HAE organotypic cultures. Single-cell and limiting-dilution analysis revealed that necroptosis is the primary cell death event in infected cells, whereas uninfected bystanders undergo apoptosis, and pyroptosis occurs later during infection. Mechanistically, necroptosis is induced by viral Z-RNA binding to Z-DNA–binding protein 1 (ZBP1) in HAE and lung tissues from patients with COVID-19. The Delta (B.1.617.2) variant, which causes more severe disease than Omicron (B1.1.529) in humans, is associated with orders of magnitude–greater Z-RNA/ZBP1 interactions, necroptosis, and disease severity in animal models. Thus, Delta induces robust ZBP1-mediated necroptosis and more disease severity.
- 12 July 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (97) , eadn0178
Initiator cell death event induced by SARS-CoV-2 in the human airway epithelium
Virus-induced cell death is a key contributor to COVID-19 pathology. Cell death induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is well studied in myeloid cells but less in its primary host cell type, angiotensin-converting enzyme 2 (ACE2)–expressing human airway epithelia (HAE). SARS-CoV-2 induces apoptosis, necroptosis, and pyroptosis in HAE organotypic cultures. Single-cell and limiting-dilution analysis revealed that necroptosis is the primary cell death event in infected cells, whereas uninfected bystanders undergo apoptosis, and pyroptosis occurs later during infection. Mechanistically, necroptosis is induced by viral Z-RNA binding to Z-DNA–binding protein 1 (ZBP1) in HAE and lung tissues from patients with COVID-19. The Delta (B.1.617.2) variant, which causes more severe disease than Omicron (B1.1.529) in humans, is associated with orders of magnitude–greater Z-RNA/ZBP1 interactions, necroptosis, and disease severity in animal models. Thus, Delta induces robust ZBP1-mediated necroptosis and more disease severity.
- Open Access
- 8 June 2022
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 18 (6) , e1010228
Fibroblast growth factor-9 expression in airway epithelial cells amplifies the type I interferon response and alters influenza A virus pathogenesis
Influenza A virus (IAV) preferentially infects conducting airway and alveolar epithelial cells in the lung. The outcome of these infections is impacted by the host response, including the production of various cytokines, chemokines, and growth factors. Fibroblast growth factor-9 (FGF9) is required for lung development, can display antiviral activityin vitro, and is upregulated in asymptomatic patients during early IAV infection. We therefore hypothesized that FGF9 would protect the lungs from respiratory virus infection and evaluated IAV pathogenesis in mice that overexpress FGF9 in club cells in the conducting airway epithelium (FGF9-OE mice). However, we found that FGF9-OE mice were highly susceptible to IAV and Sendai virus infection compared to control mice. FGF9-OE mice displayed elevated and persistent viral loads, increased expression of cytokines and chemokines, and increased numbers of infiltrating immune cells as early as 1 day post-infection (dpi). Gene expression analysis showed an elevated type I interferon (IFN) signature in the conducting airway epithelium and analysis of IAV tropism uncovered a dramatic shift in infection from the conducting airway epithelium to the alveolar epithelium in FGF9-OE lungs. These results demonstrate that FGF9 signaling primes the conducting airway epithelium to rapidly induce a localized IFN and proinflammatory cytokine response during viral infection. Although this response protects the airway epithelial cells from IAV infection, it allows for early and enhanced infection of the alveolar epithelium, ultimately leading to increased morbidity and mortality. Our study illuminates a novel role for FGF9 in regulating respiratory virus infection and pathogenesis.
- 8 June 2022
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 18 (6) , e1010228
Open AccessFibroblast growth factor-9 expression in airway epithelial cells amplifies the type I interferon response and alters influenza A virus pathogenesis
Influenza A virus (IAV) preferentially infects conducting airway and alveolar epithelial cells in the lung. The outcome of these infections is impacted by the host response, including the production of various cytokines, chemokines, and growth factors. Fibroblast growth factor-9 (FGF9) is required for lung development, can display antiviral activityin vitro, and is upregulated in asymptomatic patients during early IAV infection. We therefore hypothesized that FGF9 would protect the lungs from respiratory virus infection and evaluated IAV pathogenesis in mice that overexpress FGF9 in club cells in the conducting airway epithelium (FGF9-OE mice). However, we found that FGF9-OE mice were highly susceptible to IAV and Sendai virus infection compared to control mice. FGF9-OE mice displayed elevated and persistent viral loads, increased expression of cytokines and chemokines, and increased numbers of infiltrating immune cells as early as 1 day post-infection (dpi). Gene expression analysis showed an elevated type I interferon (IFN) signature in the conducting airway epithelium and analysis of IAV tropism uncovered a dramatic shift in infection from the conducting airway epithelium to the alveolar epithelium in FGF9-OE lungs. These results demonstrate that FGF9 signaling primes the conducting airway epithelium to rapidly induce a localized IFN and proinflammatory cytokine response during viral infection. Although this response protects the airway epithelial cells from IAV infection, it allows for early and enhanced infection of the alveolar epithelium, ultimately leading to increased morbidity and mortality. Our study illuminates a novel role for FGF9 in regulating respiratory virus infection and pathogenesis.
- 12 January 2022
- Published by American Society for Microbiology in Journal of Virology
- Vol. 96 (1) , e0114321
Interferon Alpha, but Not Interferon Beta, Acts Early To Control Chronic Chikungunya Virus Pathogenesis
Chikungunya virus (CHIKV) is a reemerging global pathogen with no effective vaccine or antiviral treatment for acute or chronic disease, and the mechanisms underlying chronic disease manifestations remain poorly defined. The significance of our research is in defining IFN-α, but not IFN-β, as an important host regulator of chronic CHIKV pathogenesis that acts within the first 48 h of infection to limit persistent viral RNA and the number of cells that survive CHIKV infection 1 month postinfection.
- 12 January 2022
- Published by American Society for Microbiology in Journal of Virology
- Vol. 96 (1) , e0114321
Interferon Alpha, but Not Interferon Beta, Acts Early To Control Chronic Chikungunya Virus Pathogenesis
Chikungunya virus (CHIKV) is a reemerging global pathogen with no effective vaccine or antiviral treatment for acute or chronic disease, and the mechanisms underlying chronic disease manifestations remain poorly defined. The significance of our research is in defining IFN-α, but not IFN-β, as an important host regulator of chronic CHIKV pathogenesis that acts within the first 48 h of infection to limit persistent viral RNA and the number of cells that survive CHIKV infection 1 month postinfection.
- 12 January 2022
- Published by Elsevier in Cell Host & Microbe
- Vol. 30 (1) , 8-9
En garde! The duel functions of MORC3
- 12 January 2022
- Published by Elsevier in Cell Host & Microbe
- Vol. 30 (1) , 8-9
En garde! The duel functions of MORC3
- Open Access
Fibroblast growth factor-9 expression in airway epithelial cells amplifies the type I interferon response and alters influenza A virus pathogenesis
Influenza A virus (IAV) preferentially infects conducting airway and alveolar epithelial cells in the lung. The outcome of these infections is impacted by the host response, including the production of various cytokines, chemokines, and growth factors. Fibroblast growth factor-9 (FGF9) is required for lung development, can display antiviral activity in vitro , and is upregulated in asymptomatic patients during early IAV infection. We therefore hypothesized that FGF9 would protect the lungs from respiratory virus infection and evaluated IAV pathogenesis in mice that overexpress FGF9 in club cells in the conducting airway epithelium (FGF9-OE mice). However, we found that FGF9-OE mice were highly susceptible to IAV and Sendai virus infection compared to control mice. FGF9-OE mice displayed elevated and persistent viral loads, increased expression of cytokines and chemokines, and increased numbers of infiltrating immune cells as early as 1 day post-infection (dpi). Gene expression analysis showed an elevated type I interferon (IFN) signature in the conducting airway epithelium and analysis of IAV tropism uncovered a dramatic shift in infection from the conducting airway epithelium to the alveolar epithelium in FGF9-OE lungs. These results demonstrate that FGF9 signaling primes the conducting airway epithelium to rapidly induce a localized, protective IFN and proinflammatory cytokine response during viral infection. Although this response protects the airway epithelial cells from IAV infection, it allows for early and enhanced infection of the alveolar epithelium, ultimately leading to increased morbidity and mortality. Our study illuminates a novel role for FGF9 in regulating respiratory virus infection and pathogenesis. Author Summary: Influenza viruses are respiratory viruses that cause significant morbidity and mortality worldwide. In the lungs, influenza A virus primarily infects epithelial cells that line the conducting airways and alveoli. Fibroblast growth factor-9 (FGF9) is a growth factor that has been shown to have antiviral activity and is upregulated during early IAV infection in asymptomatic patients, leading us to hypothesize that FGF9 would protect the lung epithelium from IAV infection. However, mice that express and secrete FGF9 from club cells in the conducting airway had more severe respiratory virus infection and a hyperactive inflammatory immune response as early as 1 day post-infection. Analysis of the FGF9-expressing airway epithelial cells found an elevated antiviral and inflammatory interferon signature, which protected these cells from severe IAV infection. However, heightened infection of alveolar cells resulted in excessive inflammation in the alveoli, resulting in more severe disease and death. Our study identifies a novel antiviral and inflammatory role for FGFs in the lung airway epithelium and confirms that early and robust IAV infection of alveolar cells results in more severe disease.
Open AccessFibroblast growth factor-9 expression in airway epithelial cells amplifies the type I interferon response and alters influenza A virus pathogenesis
Influenza A virus (IAV) preferentially infects conducting airway and alveolar epithelial cells in the lung. The outcome of these infections is impacted by the host response, including the production of various cytokines, chemokines, and growth factors. Fibroblast growth factor-9 (FGF9) is required for lung development, can display antiviral activity in vitro , and is upregulated in asymptomatic patients during early IAV infection. We therefore hypothesized that FGF9 would protect the lungs from respiratory virus infection and evaluated IAV pathogenesis in mice that overexpress FGF9 in club cells in the conducting airway epithelium (FGF9-OE mice). However, we found that FGF9-OE mice were highly susceptible to IAV and Sendai virus infection compared to control mice. FGF9-OE mice displayed elevated and persistent viral loads, increased expression of cytokines and chemokines, and increased numbers of infiltrating immune cells as early as 1 day post-infection (dpi). Gene expression analysis showed an elevated type I interferon (IFN) signature in the conducting airway epithelium and analysis of IAV tropism uncovered a dramatic shift in infection from the conducting airway epithelium to the alveolar epithelium in FGF9-OE lungs. These results demonstrate that FGF9 signaling primes the conducting airway epithelium to rapidly induce a localized, protective IFN and proinflammatory cytokine response during viral infection. Although this response protects the airway epithelial cells from IAV infection, it allows for early and enhanced infection of the alveolar epithelium, ultimately leading to increased morbidity and mortality. Our study illuminates a novel role for FGF9 in regulating respiratory virus infection and pathogenesis. Author Summary: Influenza viruses are respiratory viruses that cause significant morbidity and mortality worldwide. In the lungs, influenza A virus primarily infects epithelial cells that line the conducting airways and alveoli. Fibroblast growth factor-9 (FGF9) is a growth factor that has been shown to have antiviral activity and is upregulated during early IAV infection in asymptomatic patients, leading us to hypothesize that FGF9 would protect the lung epithelium from IAV infection. However, mice that express and secrete FGF9 from club cells in the conducting airway had more severe respiratory virus infection and a hyperactive inflammatory immune response as early as 1 day post-infection. Analysis of the FGF9-expressing airway epithelial cells found an elevated antiviral and inflammatory interferon signature, which protected these cells from severe IAV infection. However, heightened infection of alveolar cells resulted in excessive inflammation in the alveoli, resulting in more severe disease and death. Our study identifies a novel antiviral and inflammatory role for FGFs in the lung airway epithelium and confirms that early and robust IAV infection of alveolar cells results in more severe disease.
- Open Access
- 21 December 2020
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 606874
Context Is Key: Delineating the Unique Functions of IFNα and IFNβ in Disease
Type I interferons (IFNs) are critical effector cytokines of the immune system and were originally known for their important role in protecting against viral infections; however, they have more recently been shown to play protective or detrimental roles in many disease states. Type I IFNs consist of IFNα, IFNβ, IFNϵ, IFNκ, IFNω, and a few others, and they all signal through a shared receptor to exert a wide range of biological activities, including antiviral, antiproliferative, proapoptotic, and immunomodulatory effects. Though the individual type I IFN subtypes possess overlapping functions, there is growing appreciation that they also have unique properties. In this review, we summarize some of the mechanisms underlying differential expression of and signaling by type I IFNs, and we discuss examples of differential functions of IFNα and IFNβ in models of infectious disease, cancer, and autoimmunity.
- 21 December 2020
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 606874
Open AccessContext Is Key: Delineating the Unique Functions of IFNα and IFNβ in Disease
Type I interferons (IFNs) are critical effector cytokines of the immune system and were originally known for their important role in protecting against viral infections; however, they have more recently been shown to play protective or detrimental roles in many disease states. Type I IFNs consist of IFNα, IFNβ, IFNϵ, IFNκ, IFNω, and a few others, and they all signal through a shared receptor to exert a wide range of biological activities, including antiviral, antiproliferative, proapoptotic, and immunomodulatory effects. Though the individual type I IFN subtypes possess overlapping functions, there is growing appreciation that they also have unique properties. In this review, we summarize some of the mechanisms underlying differential expression of and signaling by type I IFNs, and we discuss examples of differential functions of IFNα and IFNβ in models of infectious disease, cancer, and autoimmunity.
- Open Access
6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro protease activities
A recently emerged betacoronavirus, SARS-CoV-2, has led to a global health crisis that calls for the identification of effective therapeutics for COVID-19 disease. Coronavirus papain-like protease (PLpro) is an attractive drug target as it is essential for viral polyprotein cleavage and for deconjugation of ISG15, an antiviral ubiquitin-like protein. We show here that 6-Thioguanine (6-TG) inhibits SARS-CoV-2 PLpro-catalyzed viral polyprotein cleavage and ISG15 deconjugation in cells and inhibits replication of SARS-CoV-2 in Vero-E6 cells and Calu3 cells at submicromolar levels. As a well-characterized FDA-approved orally delivered drug, 6-TG represents a promising therapeutic for COVID-19 and other emerging coronaviruses. One Sentence Summary: A repurposed drug that targets an essential enzymatic activity of SARS-CoV-2 represents a promising COVID-19 therapeutic.
Open Access6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro protease activities
A recently emerged betacoronavirus, SARS-CoV-2, has led to a global health crisis that calls for the identification of effective therapeutics for COVID-19 disease. Coronavirus papain-like protease (PLpro) is an attractive drug target as it is essential for viral polyprotein cleavage and for deconjugation of ISG15, an antiviral ubiquitin-like protein. We show here that 6-Thioguanine (6-TG) inhibits SARS-CoV-2 PLpro-catalyzed viral polyprotein cleavage and ISG15 deconjugation in cells and inhibits replication of SARS-CoV-2 in Vero-E6 cells and Calu3 cells at submicromolar levels. As a well-characterized FDA-approved orally delivered drug, 6-TG represents a promising therapeutic for COVID-19 and other emerging coronaviruses. One Sentence Summary: A repurposed drug that targets an essential enzymatic activity of SARS-CoV-2 represents a promising COVID-19 therapeutic.